What's in GC Cell Corporation's pipeline?

GC Cell Corporation has 4 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 2 in Phase 2, 1 in Phase 1.

Which companies overlap with GC Cell Corporation's portfolio?

Top competitors by shared drug class: Cook MyoSite, Seoul National University Bundang Hospital, Sewon Cellontech Co., Ltd., StemCyte, Inc., Tetec AG.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/gc-cell-corporation.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

GC Cell Corporation — Portfolio Competitive Intelligence Brief

GC Cell Corporation pipeline: 0 marketed, 0 filed, 1 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 2 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Immuncell-LC	Immuncell-LC	phase 3	Autologous cell therapy		Oncology

Therapeutic area mix

Immunology · 1
Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Cook MyoSite · 1 shared drug class
Seoul National University Bundang Hospital · 1 shared drug class
Sewon Cellontech Co., Ltd. · 1 shared drug class
StemCyte, Inc. · 1 shared drug class
Tetec AG · 1 shared drug class
TiGenix n.v. · 1 shared drug class
UnicoCell Biomed CO. LTD · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for GC Cell Corporation:

Cite this brief

Drug Landscape (2026). GC Cell Corporation — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/gc-cell-corporation. Accessed 2026-05-16.